207940KOSPIHOLDFree Access

Samsung Biologics (207940): Gangbangcheon A × Geochajesi 10/20 — Global CDMO CAPA #1, BIOSECURE Act Tailwind vs. Stretched Valuation

Testing Fibonacci 50% support. A-grade business with CAPA #1, 45.4% operating margin, and BIOSECURE Act tailwind, but PER 51x overvaluation and strike risk coexist. Split-entry strategy on pullback below ₩1,400,000.

June 5, 2026

Core Position

CDMO global CAPA #1 — BIOSECURE Act tailwind + 45% operating margin; entry timing awaits Geochajesi 14+ on pullback

Investment Thesis

Samsung Biologics holds the global CDMO CAPA #1 position at 785,000L, structurally absorbing the China CDMO gap (WuXi Biologics etc.) as the US BIOSECURE Act takes effect. After the Samsung Bioepis spin-off in 2025, it is now a pure CDMO company. FY2025 operating margin of 45.4% is exceptional for the CDMO industry. An order backlog of ~₩18T and cumulative contract wins of $15.4B underpin long-term revenue visibility. However, the current implied PER of ~51x exceeds the high-growth K-PER ceiling of 35x, meaning expectations are largely priced in. Gangbangcheon A × Geochajesi 10/20 — business quality is A-grade but current price is stretched. Staged-entry strategy on a pullback to ₩1,400,000 or Geochajesi reconfirmation at 14+ is rational.

① Non-Financial — CAPA #1 + Triple Moat + BIOSECURE Act Structural Tailwind

Samsung Biologics' moat is a triple moat: switching costs, cost structure, and brand. FDA/EMA certification + multi-year technology transfer create switching costs; global largest single campus drives economies of scale; 17 of Big Pharma Top 20 are customers. The BIOSECURE Act phases out China CDMO usage in the US by 2032, and the GSK Rockville plant acquisition partially hedges tariff risk. ADC, CGT, and mRNA modality expansion demonstrates post-mAb CAPA relevance. Key risks: the May 2026 full strike (estimated ₩150B loss), governance exposure to Samsung owner issues, and pending tariff detail finalization. → Full 5-Layer analysis in the Non-Financial tab.

② Validator — Gangbangcheon A × Geochajesi 10/20 = Quality Business, Await Timing

4 of 5 Gangbangcheon steps passed (1–4 ✅, 5 ⚠️). Steps 1–3: CDMO TAM 12% CAGR, global CAPA #1, long-term contract business model — all cleared. Step 4: P↑Q↑C↓ best combination — FY25 operating margin 45.4% record high passed. Step 5 not met: current implied PER ~51x vs. K-PER ceiling 35x — overvalued. Base scenario upside only +13% — below the buy conviction threshold. Geochajesi 10/20 — Volume 2 (daily avg 31,451 shares, short-term flow unconfirmed) + Chart 2 (-24% off ATH, mixed MA alignment) + Catalyst 4 (BIOSECURE Act + Q1 FY26 46.2% margin record + Rockville acquisition + tariff uncertainty) + Market 2 (KOSPI foreign net selling, rate-cut positive). No veto triggered. → Full Gangbangcheon steps, K-PER, and Geochajesi detail in the Validator tab.

③ Technical — Testing Fibonacci 50% Support; Union Risk Resolution Determines Direction

5-wave advance from 52-week low (₩982,000) to 52-week high (₩1,987,000) complete; currently in A-B-C correction. Current price ₩1,509,000 is just above the Fibonacci 50% retracement (₩1,484,500) — testing key support. A break below opens Fib 61.8% (₩1,367,000). Short-term MA alignment is estimated to be bearish. Recommended Scenario A (3-tranche split): Tranche 1 ₩1,400,000–1,450,000, Tranche 2 ₩1,300,000–1,370,000, avg ₩1,362,000 basis, stop ₩1,200,000, Target 1 ₩1,700,000–1,750,000, R:R 2.1. Key trigger: union negotiation result (resolution → bounce; prolonged → Q2 earnings shock) + Q2 earnings (July target). → Full 3 scenarios, Fibonacci, RSI chart in the Technical tab.

Key Metrics

Price / Market Cap

1,509,000원 / 107조

implied PER ~51배

52-Week Range

982,000~1,987,000원

현재 고점 대비 -24%

FY2025 Operating Margin

45.4%

+7.4%p YoY — 신고치

Order Backlog

~18조원

누적 수주 $154억

Total CAPA

78.5만L

글로벌 1위

Gangbangcheon × Geochajesi

A × 10/20

관심 종목, 타이밍 대기

Bull Case

BIOSECURE Act — structural absorption of China CDMO (WuXi Biologics etc.) US market exclusion
Global CAPA #1 (785,000L) + Plant 5 complete + Plant 6 groundbreaking — infrastructure moat secured
FY2025 operating margin 45.4% record high — industry-best operational efficiency sustained
ADC, CGT, mRNA modality expansion — post-mAb portfolio diversification extends growth runway
17 of Big Pharma Top 20 as customers — high switching cost foundation supports long-term revenue visibility

Bear Case

Current implied PER ~51x — 45% overvalued vs. K-PER ceiling 35x; most growth expectations priced in
May 2026 full strike — estimated ₩150B loss; Q2 earnings shock risk could materialize
US pharmaceutical tariff scope unconfirmed — CDMO applicability confirmation could hurt margins
Plant 5 revenue recognition delay + structural labor cost increases — 2026 consensus downgrade pressure
5-month MA alignment remains bearish despite -24% from ATH — technical downtrend intact

Rating:HOLD207940

Technical Summary

Current price ₩1,509,000 is -24% off the 52-week high (₩1,987,000). Testing a potential inflection point just above the Fibonacci 50% retracement (₩1,484,500). Short-term MA alignment is estimated bearish, RSI at 40–50 neutral zone. Union risk resolution is the key near-term directional variable.

Samsung Biologics Technical Analysis — Price Structure, Fibonacci, RSI (2025 Low–Jun 2026)

Support

1,484,500원 (피보나치 50%) · 1,367,000원 (피보나치 61.8%) · 1,200,000~1,250,000원 (중기 이평) · 982,000원 (52주 저점)

Resistance

1,603,000원 (피보나치 38.2%) · 1,700,000~1,750,000원 (1차 저항, 전고점 매물대) · 1,987,000원 (52주 고점)

Trend Analysis

Short-term (20-day MA): Estimated bearish. -24% decline from ATH (₩1,987,000) to current (₩1,509,000) — estimated below 20-day MA. Medium-term (60-day MA): Estimated turning bearish. Post-golden-cross MA alignment is mixed → short-term bearish alignment forming. Long-term (120-day MA): Recovery trend from 52-week low (₩982,000) intact but mid-term correction underway. Fibonacci 50% retracement (₩1,484,500) is the critical support — break opens Fib 61.8% (₩1,367,000) retest path.

Momentum & Indicators

RSI(14): Estimated 40–50 (given -24% from ATH, not oversold — neutral-to-weak zone). From RSI 75+ at the ATH, now normalizing toward neutral. MACD: Estimated dead cross forming or completed in short-term bearish alignment → weak bias. Volume: Daily avg 31,451 shares — moderate. OBV: Neutral estimated. Bollinger Bands: Tracking lower band direction after ATH breakdown.

Key Technical Points

Resistance 1

₩1,700,000–1,750,000 — analyst target price floor + prior ATH supply zone. Break opens Fibonacci 23.6% zone

Resistance 2 (52-Week High)

₩1,987,000 — Jan 15, 2026 52-week high. Break confirms trend reversal and new ATH attempt

Support 1 (Fibonacci 50%)

₩1,484,500 — just below current price. Break opens Fib 61.8% (₩1,367,000) retest path

Support 2 (Fibonacci 61.8%)

₩1,367,000 — Tranche 2 entry zone. Lower bound of the staged buy zone

Fibonacci

Basis: Low ₩982,000 → High ₩1,987,000 (range ₩1,005,000). 23.6%=₩1,750,000 / 38.2%=₩1,603,000 / 50%=₩1,484,500 / 61.8%=₩1,367,000. Current ₩1,509,000 — just above 50% retracement

Trading Scenarios

Scenario A — Conservative Split Entry (Recommended)R:R 2.1

Entry

Tranche 1: ₩1,400,000–1,450,000 (Fib 50–61.8% zone) / Tranche 2: ₩1,300,000–1,370,000 (61.8% retracement), avg ₩1,362,000

Stop

₩1,200,000 (below second support level)

Target

T1: ₩1,700,000–1,750,000 / T2: ₩1,987,000 (52-week high retest)

R:R 2.1 meets threshold. Execute Tranche 1 after union resolution is confirmed. Tranche 2 on Fib 61.8% touch. 3-tranche entry, total weight 15–20% recommended.

Scenario B — Aggressive Immediate EntryR:R 1.5

Entry

Immediate entry at current price ₩1,509,000

Stop

₩1,350,000 (-10.5%)

Target

T1: ₩1,750,000 (+16.0%)

R:R 1.5 barely meets threshold. Immediate entry before union risk resolution is risky. Half-weight only recommended. Prolonged May 2026 strike could trigger earnings shock.

Scenario C — Buy the Bounce ConfirmationR:R 1.3

Entry

Enter on ₩1,600,000+ bounce with volume confirmation

Stop

₩1,480,000 (Fibonacci 50% break)

Target

₩1,750,000 (first resistance)

R:R 1.3 below minimum threshold. Gap-up chase scenario after union agreement announcement. High entry price makes R:R inferior. Short-swing-trade use only.

Bullish Signals

↑

Fibonacci 50% retracement (₩1,484,500) near-support — high-probability medium-term bounce inflection

↑

BIOSECURE Act + Q1 FY26 operating margin 46.2% record — fundamentals intact

↑

Consensus target ₩2,124,737 vs. current -29% discount — valuation appeal forming

↑

Plant 6 groundbreaking (2027 target) — long-term CAPA expansion story intact

↑

19 analyst coverage, avg BUY (4.0) — institutional support floor

Bearish Risks

↓

-24% off ATH (₩1,987,000) — estimated short-term bearish MA alignment, technical downward momentum

↓

May 2026 full strike (est. ₩150B loss) — Q2 earnings shock risk could materialize

↓

Current implied PER 51x — 46% overvalued vs. high-growth K-PER ceiling 35x

↓

Tariff scope unconfirmed — CDMO applicability risk creates consensus downgrade pressure

↓

Bounce volume unconfirmed — insufficient accumulation strength for resistance breakout confidence

Editor Note

Testing a potential inflection at Fibonacci 50% support (₩1,484,500). The business is A-grade but the current PER of 51x embeds near-term downside risk. Union negotiation outcome is the single most important near-term directional variable. Risk management rules: hold ₩1,200,000 stop; no more than 1–2% of total assets at risk. Split entry within 15–20% total weight. Consider adding to position when Geochajesi 14+ AND KOSPI stabilization are simultaneously confirmed.

* Technical analysis is based on historical data and does not guarantee future returns. Final investment decisions are your own responsibility.

Samsung Biologics Technical Analysis — Price, Fibonacci, RSI

Switching Cost & Moat

Moat Strength by Type

Switching Costs

FDA/EMA regulatory certification + technology transfer requires minimum 18–24 months. Big Pharma customer switching costs are extremely high. Long-term contract structure (average 3–5 years).

Very Strong

Cost Structure

World's largest single campus (Songdo) economies of scale. Operating margin 45.4% — highest in global CDMO industry. Fixed cost dilution effect as CAPA expands.

Strong

Brand (B2B)

17 of Big Pharma Top 20 as customers. Proven execution: Moderna vaccine GMP approval + production within 5 months. $15.4B cumulative contract wins.

Strong

Technology / Patents

In-house cell line and process development platforms, tacit knowledge domain. Core competency is process efficiency rather than foundational patents. Technology in new modalities unproven at scale.

Medium

Samsung Biologics' moat is a triple moat: switching costs, cost structure, and brand. FDA/EMA regulatory certification and technology transfer (minimum 18–24 months) create switching costs; the world's largest single-campus scale drives economies of scale. Being supplier to 17 of Big Pharma Top 20 proves top-tier B2B trust as brand value. Technology/patent moat is medium (process platform + tacit knowledge). Network effects are weak (not a platform model). While #1 globally by CAPA (785,000L), being #2 by revenue (vs. Lonza) shows the moat's ceiling.

Management & Governance

John Rim, President & CEO (born 1961). Columbia chemical engineering → Stanford M.S. → Northwestern MBA. Booz & Company consultant → Yamanouchi US CFO → Genentech CFO → Roche US CFO → Samsung Biologics CEO since 2021, reappointed November 2024. Global Big Pharma finance experience is a direct strength in contract negotiation and customer trust-building. Risks: Samsung Group governance structure (Lee Jae-yong → Samsung C&T 43.6% → Samsung Biologics) and the 2018 accounting controversy as historical precedent. No dual-class shares — institutional shareholders can exercise governance influence.

Competitive Landscape

Lonza (LONN SW)

Very High

Global CDMO revenue #1. Integrated small molecule + biologics CDMO. Switzerland HQ, 22 global manufacturing sites. ADC manufacturing capabilities ahead of Samsung.

WuXi Biologics (2269 HK)

Medium (Being Excluded)

China #1 CDMO. BIOSECURE Act phases out US contracts 2027–2032 → direct Samsung Biologics beneficiary. Still a competitor in Asian and European markets.

Boehringer Ingelheim (Private)

Medium

Private German company. Specialized in antibody and biologics CDMO. High insourcing ratio limits external contract volume. Strengthening ADC and mRNA pipeline.

Fujifilm Diosynth (TYO: 4901)

Medium (Rising)

Fujifilm CDMO division. Aggressively expanding in US and Europe. CGT and mRNA capabilities growing rapidly. Smaller CAPA than Samsung but rising new-modality competitiveness.

Global CDMO competitive landscape: #1 Lonza (Switzerland), #2 Samsung Biologics, #3 WuXi Biologics (China, being excluded), #4 Boehringer Ingelheim (Germany), #5 Fujifilm (Japan). Samsung's differentiation: CAPA economies of scale + cost competitiveness + Korea production infrastructure. Medium-term threat: Big Pharma insourcing and specialist CDMO entry in new modalities (ADC, CGT, mRNA). BIOSECURE Act benefit to accrue gradually 2027–2032. Consensus target ₩2,124,737 (+41% from current); Samsung Securities ₩1,800,000 (lowered for tariff/labor uncertainty).

ESG & Summary

Samsung Biologics contributed to global pharmaceutical access by producing Moderna COVID vaccines with GMP approval within 5 months in 2021. As a CDMO, direct carbon emissions are lower than manufacturing but energy-intensive bioreactor operations are the key environmental challenge. Governance: Samsung C&T / Lee Jae-yong linkage creates owner risk. High accounting transparency sensitivity since the 2018 controversy. The May 2026 full strike revealed structural labor relations management challenges. ESG disclosure: Sustainability report published; carbon neutrality roadmap under development.

Key Risks

US Tariff Risk

Trump administration's 100% pharmaceutical tariff announcement — CDMO scope uncertain. US revenue share 25.8% (2024). GSK Rockville acquisition ($280M) provides partial buffer, but margin risk if tariff details are finalized. Consensus already beginning to price in downward revisions.

Labor Strike Risk

Full strike and compliance protests in May 2026 — estimated ₩150B loss. Actual impact to be confirmed at Q2 earnings (July target). Prolonged strike could damage customer trust. Risk of order diversion to competing CDMOs during production disruptions.

Valuation Overvaluation Risk

Current implied PER ~51x — 45%+ premium vs. high-growth K-PER ceiling (35x). Base scenario upside +13%, conservative -16%. Rapid de-rating risk on earnings miss or contract slowdown. Plant 5 revenue recognition delay creates consensus downgrade pressure.

Post-mAb New Modality Transition Risk

ADC, CGT, and mRNA require different manufacturing processes from mAb — separate facilities and technology needed. If new modality adaptation is slow, medium-to-long-term CAPA utilization could decline. ADC co-development with LigaChem Biosciences underway but commercial-scale results unconfirmed.

Gangbangcheon 4/5 passed

4 of 5 Gangbangcheon steps passed (Grade A). CDMO structural growth, global #1 position, long-term contract business model, and 45.4% operating margin financial quality all cleared. However, current implied PER 51x limits K-PER base upside to +13% — Step 5 not met. Geochajesi 10/20 — quality business, await timing. Split-entry principle on pullback below ₩1,400,000 or Geochajesi 14+ confirmation.

Gangbangcheon 5-Step Checklist

✓

Step 1

Industry & Infrastructure ✅ — Global Biologics CDMO Market 12% CAGR

Global biologics CDMO market projected to grow at 12% CAGR to ~$38B by 2030, driven by Big Pharma outsourcing expansion, increasing new biologics approvals, and patent cliffs. BIOSECURE Act exclusion of China CDMOs creates additional upside for Korean and European CDMOs. ADC, mRNA, and CGT new modalities expand total addressable market further. Step 1 passed.

✓

Step 2

Market Position A ✅ — Global CAPA #1, 17 Big Pharma Customers

CAPA 785,000L — global CDMO #1. 17 of Big Pharma Top 20 as customers. Cumulative contract wins exceed $15.4B. Pricing power confirmed by long-term contract structure (3–5 years) — 45.4% operating margin as evidence. However, #2 by revenue (behind Lonza). Step 2 passed.

✓

Step 3

Business Model ✅ — Long-Term Contract CDMO + New Modality Expansion

Long-term contract B2B structure. High customer switching costs sustain high renewal rates. Vertical integration CDO→CMO→DP service bundle drives per-unit revenue increases. US Rockville plant acquisition enables tariff hedging and expands US customer service. ADC, CGT, mRNA new modality portfolio expanding. Step 3 passed.

✓

Step 4

Financial Quality ✅ — P↑Q↑C↓ = Operating Margin 45.4% Record High

FY2025 revenue ₩4.56T (+30%), operating income ₩2.07T, operating margin 45.4% (record). P↑Q↑C↓ = best-case quadrant. FY2023→2025 revenue CAGR +24.5%. ROA ~8%, ROE ~14% (estimated). However, FCF not confirmed, labor cost increases, and strike losses expand FY2026 estimate uncertainty. Step 4 conditional pass.

✗

Step 5

K-PER Upside ⚠️ — Base +13%, Conservative -16%

Current market cap ₩107T, FY25 operating income ₩2.07T. K-PER range: high-growth innovative 20–35x. Base scenario (25% CAGR, K-PER 30x) → ₩121.3T, upside +13% — below buy conviction threshold (>20%). Conservative (20% CAGR, K-PER 25x) → ₩89.4T, -16%. Optimistic (30% CAGR, K-PER 35x) → +48% but growth expectations largely priced in. Step 5 not met.

K-PER Scenario Analysis (3-Year Target)

Company type: high-growth CDMO innovative → K-PER 20–35x applied. Current operating income (FY25) ₩2.07T, current market cap ₩107T (implied PER 51x). 3-year forward operating income estimated (FY2028 basis). 3 target caps by growth scenario.

Scenario	Annual Growth	Non-GAAP Profit	Applied PER	Target Cap	Upside
Optimistic	+30% CAGR	4조5,338억	35x	158.7조	+48%
Base	+25% CAGR	4조434억	30x	121.3조	+13%
Conservative	+20% CAGR	3조5,765억	25x	89.4조	-16%

Geochajesi Score (10/20)

Volume2/5

Daily avg volume 31,451 shares (moderate). 19 analyst coverage, avg BUY recommendation (4.0) maintained. Short-term foreign/institutional net buying data unavailable. Bounce-zone volume confirmation needed.

Chart2/5

-24% off ATH (₩1,987,000). Short-term MA estimated bearish (real-time data unavailable). Testing Fibonacci 50% (₩1,484,500) support — potential inflection candidate. Bounce without volume confirmation has low credibility.

Catalyst4/5

BIOSECURE Act — structural China CDMO exclusion benefit [A]. Q1 FY26 46.2% operating margin record [A]. GSK Rockville acquisition — partial tariff hedge [B]. Union strike prolongation risk — Q2 earnings uncertainty [negative].

Market Condition2/5

KOSPI foreign net selling trend — supply-demand pressure on large caps broadly. Bio sector maintaining partial relative strength. Rate-cut trajectory positive. KRW/USD stabilization positive.

Total10/20

Entry Strategy (3 Tranches)

Tranche 1 (Fib 50–61.8% Zone)1,400,000~1,450,000원

After Fibonacci 50% (₩1,484,500) break, in ₩1,400,000–1,450,000 zone. Execute after union negotiation outcome confirmed. 1/2 tranche.

Tranche 2 (Fib 61.8% Zone)1,300,000~1,370,000원

Near Fibonacci 61.8% (₩1,367,000). Execute on bounce candle confirmation. Target avg entry ₩1,362,000.

Tranche 3 (Additional Downside Buffer)1,200,000~1,250,000원

Near secondary support. Best-price opportunity on surprise events like earnings shock. Total weight within 15–20% principle.

Exit Triggers

₩1,200,000 break → stop-loss triggered. Below secondary support floor

Contract miss (new contract growth -20%+ YoY) → full position reassessment

Conservative K-PER upside deepens negative + veto trigger → reduce weight

Operating margin below 38% for 2 consecutive quarters → high-margin thesis impaired, adjust position

₩1,987,000 (52-week high) break to new ATH → partial exit 25–50%

⚖

Portfolio Weight Recommendation

No new entry at current price (₩1,509,000). Execute Tranche 1 (5–8% of portfolio) only when Geochajesi 14+ AND ₩1,400,000 pullback are simultaneously met. Total target weight 15–20%. Sequentially add after union risk resolution confirmed. Dollar-cost averaging at current price acceptable for 3–5 year hold horizon (not with funds needed by maturity).

Editor Note

Gangbangcheon A × Geochajesi 10/20. Business quality is A-grade but timing is not yet. Technical bounce from Fibonacci 50% support is possible, but PER 51x valuation burden and union strike risk coexist. Conditions for Geochajesi 14+: volume confirmation (institutional net buying increase) + MA alignment improvement (20-day MA recovery) + catalyst confirmation (union agreement + Q2 earnings hold). Until conditions are met, the principle is watchlist status and wait.

Financial Data

Samsung Biologics fiscal year: Jan 1–Dec 31. Samsung Bioepis spin-off announced May 2025; Samsung Epis Holdings separately listed November 2025. FY2025 onwards reflects pure CDMO surviving entity.

Period	Revenue	Growth	Op. Income	Op. Margin
FY2023ROA ~8%, ROE ~14% (estimated)	2조9,388억원	—	1조570억원	36.0%
FY2024P↑Q↑C↓ growth combination — meets Step 4 criteria	3조4,971억원	+19.0%	1조3,214억원	37.8%
FY2025Record high. Pure CDMO basis after Bioepis spin-off. Q1 FY26 OPM 46.2% further record	4조5,570억원	+30.3%	2조692억원	45.4%

GAAP vs Non-GAAP Note

P↑Q↑C↓ best-case combination achieved FY2025 operating margin 45.4%. Consolidated vs. standalone financials being restructured after November 2025 Bioepis spin-off listing. Post-FY2025 consolidation reflects pure CDMO entity. Tariff risk (amount TBD) and strike losses (est. ₩150B) being incorporated into FY2026 profit estimates. Next earnings: July 2026 (Q2 preliminary results).

Key Valuation Metrics

Implied PER (FY25)

~51배

Exceeds K-PER high-growth ceiling (35x) — growth expectations priced in

Operating Margin (FY25)

45.4%

Industry-best globally; +7.6%p vs FY24 37.8%

Total CAPA

78.5만L

Global #1. Plant 6 (+180,000L) targets 965,000L by 2027

Order Backlog

~18조원

Cumulative contract wins exceed $15.4B (as of Q3 2024)

ROA / ROE

~8% / ~14%

Estimated based on post-spin-off balance sheet

* GAAP basis. All figures are estimates based on public information and are not investment advice.

Same Exchange

← Back to Company Analysis